Development and use of sulodexide in vascular diseases: implications for treatment

References

• Afratis N Gialeli C Nikitovic D Glycosaminoglycans: key players in cancer cell biology and treatment FEBS J 2012 279 1177 1197 22333131
   PubMed Web of Science ®Google Scholar
• Gandhi NS Mancera RL The structure of glycosaminoglycans and their interactions with proteins Chem Biol Drug Des 2008 72 6 455 482 19090915
   PubMed Web of Science ®Google Scholar
• Rudd TR Skidmore MA Guimond SE Glycosamino-glycan origin and structure revealed by multivariate analysis of NMR and CD spectra Glycobiology 2009 19 1 52 67 18832453
   PubMed Web of Science ®Google Scholar
• Asimakopoulou AP Theocharis AD Tzanakakis GN Karamanos NK The biological role of chondroitin sulfate in cancer and chondroitin-based anticancer agents In Vivo 2008 22 3 385 389 18610752
   PubMed Web of Science ®Google Scholar
• Lauder RM Chondroitin sulphate: a complex molecule with potential impacts on a wide range of biological systems Complement Ther Med 2009 17 56 62 19114230
   PubMed Web of Science ®Google Scholar
• Tollefsen DM Vascular dermatan sulphate and heparin cofactor II Prog Mol Biol Transl Sci 2010 93 351 372 20807652
   PubMed Web of Science ®Google Scholar
• Malavaki CJ Theocharis AD Lamari FN Heparan sulfate: biological significance, tools for biochemical analysis and structural characterization Biomed Chromatogr 2011 25 1–2 11 20 21204109
   PubMed Web of Science ®Google Scholar
• Mulloy B Structure and physicochemical characterisation of heparin Handb Exp Pharmacol 2012 207 77 98 22566222
   PubMedGoogle Scholar
• Dreyfuss JL Regatieri CV Jarrouge TR Cavalheiro RP Sampaio LO Nader HB Heparan sulfate proteoglycans: structure, protein interactions and cell signaling An Acad Bras Cienc 2009 81 3 409 429 19722012
   PubMed Web of Science ®Google Scholar
• Bick RL Frenkel EP Walenga J Fareed J Hoppensteadt DA Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology and clinical use Hematol Oncol Clin North Am 2005 19 1 1 51 15639107
   PubMed Web of Science ®Google Scholar
• Bianchini Pinventor Opocrin SRLassignee Method for preparing glucoronyl-glucosamino-glycan sulphates exhibiting antilipasaemic activity United States patent US 3936351 2 3 1976
   Google Scholar
• Silvestro L Lanzarotti E Marchi E Human pharmacokinetics of glycosaminoglycans using deuterium-labeled and unlabeled substances: evidence for oral absorption Semin Thromb Hemost 1994 20 281 292 7824963
   PubMed Web of Science ®Google Scholar
• Cosmi B Cini M Legnani C Pancani C Calanni F Coccheri S Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans Thromb Res 2003 109 5–6 333 339 12818259
   PubMed Web of Science ®Google Scholar
• Iacoviello L D’Adamo MC Pawlak K Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis Thromb Haemost 1996 76 6 1102 1107 8972038
   PubMed Web of Science ®Google Scholar
• Di Carlo V Agnelli G Prandoni P Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. DOS (Dermatan sulphate Oncolologic Surgery) Study Group Thromb Haemost 1999 82 1 30 34 10456450
   PubMed Web of Science ®Google Scholar
• Mannello F Raffetto JD Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research Am J Transl Res 2011 3 2 149 158 21416057
   PubMed Web of Science ®Google Scholar
• Mattana P Mannello F Ferrari P Agus GB Vascular pathologies and inflammation: the antinflammatory properties of sulodexide J Vasc Endovasc Surg 2012 19 1 7
   Google Scholar
• Plichta JK Radek KA Sugar coating wound repair: a review of FGF10 and DS in wound healing and their potential application in burn wounds J Burn Care Res 2012 33 299 310 22561305
   PubMed Web of Science ®Google Scholar
• Milani MR Busutti L Breccia A Pharmacokinetics of sulodexide evaluation from 131-labelled fast-moving heparin after single intravenous and oral administration on man at different doses Brit J Clin Res 1992 3 161 178
   Google Scholar
• Marchi E Barbanti M Milani R Organ glycosaminoglycan distribution after intravenous and oral administration in rats Semin Thromb Hemost 1994 20 297 300 7824965
   PubMed Web of Science ®Google Scholar
• Ofosu FA Pharmacological actions of sulodexide Semin Thromb Hemost 1998 24 127 137 9579633
   PubMed Web of Science ®Google Scholar
• Adiguzel C Iqbal O Hoppensteadt D Comparative anticoagulant and platelet modulatory effects of enoxaparin and Sulodexide Clin Appl Thromb Hemost 2009 15 5 501 511 19703818
   PubMed Web of Science ®Google Scholar
• Harenberg J Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide Med Res Rev 1998 18 1 20 9436179
   PubMed Web of Science ®Google Scholar
• Borawski J Dubowski M Rydzewska-Rosolowska A Mysliwiec M Intravenous and oral Sulodexide versus coagulation activation markers in humans Clin Appl Thromb Hemost 2009 15 5 596 598 19910295
   PubMed Web of Science ®Google Scholar
• Borawski J Naumnik B Dubowski M Mysliwiec M Full-length TFPI release by heparinoid Sulodexide Clin Appl Thromb Hemost 2010 16 4 485 487 20647229
   PubMed Web of Science ®Google Scholar
• Coccheri S Scondotto G Agnelli G Palazzini E Zamboni V Sulodexide in the treatment of intermittent claudication. Results of a randomized, double blind, multicentre, placebo-controlled study Eur Heart J 2002 23 13 1057 1065 12093059
   PubMed Web of Science ®Google Scholar
• Callas DD Hoppensteadt DA Jeske W Comparative pharmacologic profile of a glycosaminoglycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoid Semin Thromb Hemost 1993 19 Suppl 1 49 57 8362269
   PubMed Web of Science ®Google Scholar
• Ceriello A Quatrano A Marchi E Barbanti M Giugliano D Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide Diabetes Metab 1993 19 2 225 229
   Web of Science ®Google Scholar
• Buchanan MR Liao P Smith LJ Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors:: importance of heparin cofactor II Thromb Res 1994 74 463 475 8085247
   PubMed Web of Science ®Google Scholar
• Hornstra G Vendelmans-Starrenburg A Induction of experimental arterial occlusive thrombi in rats Atherosclerosis 1973 17 3 369 382 4714807
   PubMed Web of Science ®Google Scholar
• Andriuoli G Mastacchi R Barbanti M Antithrombotic activity of a glycosaminoglycan (sulodexide) in rats Thromb Res 1984 34 1 81 86 6729771
   PubMed Web of Science ®Google Scholar
• Tarugi P Tiozzo-Costa Barbanti M Effect of sulodexide, a heparin-like compound, on experimental atherosclerosis in the rabbit Med Sci Res 1987 15 1071 1072
   Google Scholar
• Barbanti M Guizzardi S Calanni F Marchi E Babbini M Antithrombotic and thrombolytic activity of Sulodexide in rats Int J Clin Lab Res 1992 22 3 179 184 1520915
   PubMedGoogle Scholar
• Agrati AM Mauro M Savasta C A double-blind, cross-over, placebo-controlled study of the profibrinolytic and antithrombotic effects of oral sulodexide Adv Ther 1992 9 147 155
   Web of Science ®Google Scholar
• Mauro M Ferraro G Palmieri GC Profibrinolytic and antithrombotic effects of sulodexide oral administration: a double-blind, cross-over, placebo-controlled study Curr Ther Res 1992 51 342 350
   Web of Science ®Google Scholar
• Mannarino E Pasqualini L Ciuffetti G Effect of oral administration of sulodexide on fibrinolysis and plasma viscosity: a pilot study Drug Invest 1992 4 346 350
   Web of Science ®Google Scholar
• Cerletti C Rajtar G Marchi E Interaction between glycosaminoglycans, platelets and leukocytes Semin Thromb Hemost 1994 20 245 253 7824958
   PubMed Web of Science ®Google Scholar
• Mannello F Medda V Ligi D Raffetto JD Glycosaminoglycan Sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases Curr Vasc Pharmacol 2013 11 3 354 365 22724470
   PubMed Web of Science ®Google Scholar
• Borawski J Dubowski M Pawlak K Effect of Sulodexide on plasma transforming growth factor ß1 in healthy volunteers Clin Appl Thromb Hemost 2010 16 60 65 19117965
   PubMed Web of Science ®Google Scholar
• Tiozzo R Cingi MR Pietrangelo A Effect of heparin-like compounds on the in vitro proliferation and protein synthesis of various cell types Arzneimittelforschung 1989 39 1 15 20 2719740
   PubMed Web of Science ®Google Scholar
• Borawski J Dubowski M Pawlak K Mysliwiec M Sulodexide induces hepatocyte growth factor release in humans Eur J Pharmacol 2007 558 1–3 167 171 17258198
   PubMed Web of Science ®Google Scholar
• Broekhuizen LN Lemkes BA Mooij HL Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus Diabetologia 2010 53 2646 2655 20865240
   PubMed Web of Science ®Google Scholar
• Kristova V Liskova S Sotnikova R Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats Physiol Res 2008 57 491 494 18597586
   PubMed Web of Science ®Google Scholar
• Vasquez J Mathison Y Romero-Vecchione E Effect of sulodexide on aortic vasodilation capacity and associated morphological changes in rats with streptozotocin-induced diabetes Invest Clin 2010 51 4 467 477 Spanish 21365875
   PubMed Web of Science ®Google Scholar
• Crepaldi G Fellin R Calabrò A Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use Atherosclerosis 1990 8 13 233 243 2190565
   PubMed Web of Science ®Google Scholar
• Lunetta M Salanitri T Lowering of plasma viscosity by the oral administration of the glycosaminoglycan sulodexide in patients with peripheral vascular disease J Int Med Res 1992 20 1 45 53 1568519
   PubMed Web of Science ®Google Scholar
• Cospite M Ferrara F Cospite V Sulodexide and the microcirculatory component in microphlebopathies Curr Med Res 1992 13 1 56 60
   PubMed Web of Science ®Google Scholar
• Park HY Kang S Kim GY Inhibition of neointimal proliferation of rat carotid artery by sulodexide J Korean Med Sci 1997 12 3 210 214 9250916
   PubMedGoogle Scholar
• Bergan JJ Schmid-Schonbein GW Smith PD Chronic venous disease N Engl J Med 2006 355 5 488 498 16885552
   PubMed Web of Science ®Google Scholar
• Andreozzi GM Sulodexide in the treatment of chronic venous disease Am J Cardiovasc Drugs 2012 12 2 73 81 22329592
   PubMed Web of Science ®Google Scholar
• Evans CJ Fowkes FG Ruckley CV Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study J Epidemiol Community Health 1999 53 3 149 153 10396491
   PubMed Web of Science ®Google Scholar
• Maurins U Hoffman BH Losch C Distribution and prevalence of reflux in the superficial and deep venous system in the general population: results from the Bonn Vein Study, Germany J Vasc Surg 2008 48 3 680 687 18586443
   PubMed Web of Science ®Google Scholar
• Eklof B Rutherford RB Bergan JJ Revision of the CEAP classification for chronic venous disorders: consensus statement J Vasc Surg 2004 40 6 1248 1252 15622385
   PubMed Web of Science ®Google Scholar
• Bergan JJ Pascarella L Schmid-Schoenbein GW Pathogenesis of primary chronic venous disease: Insights from animal models of venous hypertension J Vasc Surg 2008 47 1 183 192 18178472
   PubMed Web of Science ®Google Scholar
• Cohen JM Akl EA Khan SR Pharmacologic and compression therapies for post thrombotic syndrome Chest 2012 141 2 308 320 22315114
   PubMed Web of Science ®Google Scholar
• Marinović Kulišić S Lupi D Pharmacological treatment in patients with chronic venous disease Acta Dermatovenerol Croat 2012 20 3 197 200 23069307
   PubMed Web of Science ®Google Scholar
• Lauver AD Lucchesi BR Sulodexide: a renewed interest in this glycosaminoglycan Cardiovasc Drug Rev 2006 24 3–4 214 226 17214598
   PubMed Web of Science ®Google Scholar
• Lei Y Zheng Z Wang Y Sulodexide may alleviate neointimal hyperplasia by inhibiting angiopoietin-2 in an arteriovenous fistula model Mol Med Rep 2013 7 3 831 835 23358592
   PubMed Web of Science ®Google Scholar
• Saviano M Maleti O Liguori L Double-blind, double-dummy, randomized, multicentre clinical assessment of the efficacy, tolerability and dose-effect relationship of Sulodexide in chronic venous insufficiency Curr Med Res Opin 1993 13 2 76 108
   Web of Science ®Google Scholar
• Gloviczki P Camerota AJ Dalsing MC The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the American Society for Vascular Surgery and the American Venous Forum J Vasc Surg 2011 53 5S 2S 28S 21536172
   PubMed Web of Science ®Google Scholar
• Kahn SR The post-thrombotic syndrome: prognosis and pitfalls Br J Haematol 2006 134 4 357 365 16822286
   PubMed Web of Science ®Google Scholar
• Palareti G Legnani C Cosmi B Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and carriers of congenital thrombophilia Circulation 2003 108 39 313 318 12847064
   PubMed Web of Science ®Google Scholar
• Palareti G Leali N Coccheri S Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy Lancet 1996 348 423 428 8709780
   PubMed Web of Science ®Google Scholar
• Connors JM Extended treatment of venous thromboembolism N Engl J Med 2013 368 8 767 769 23425170
   PubMed Web of Science ®Google Scholar
• Becattini C Agnelli G Schenone A WARFASA Investigators Aspirin for preventing the recurrence of venous thromboembolism N Engl J Med 2012 366 1 1959 1967 22621626
   PubMed Web of Science ®Google Scholar
• Brighton TA Eikelboom JW Mann K ASPIRE Investigators Low-dose aspirin for preventing recurrent venous thromboembolism N Engl J Med 2012 367 21 1979 1987 23121403
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA Lin KJ Hernandez-Diaz S Johansson S Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications Circulation 2011 123 1108 1115 21357821
   PubMed Web of Science ®Google Scholar
• Cirujeda JL Granado PC A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep vein thrombosis Angiology 2010 57 1 53 64 16444457
   PubMed Web of Science ®Google Scholar
• Errichi BM Cesarone MR Belcaro G Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry Angiology 2004 55 3 243 249 15156256
   PubMed Web of Science ®Google Scholar
• Andreozzi GM Palareti G Rationale and study design of the SURVET trial (Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis) Proceedings of the 21st International Congress on Thrombosis July 6–9, 2010 Milan, Italy Abstract; p302
   Google Scholar
• Nicolaides AN Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration Angiology 2005 56 S11 9 16193221
   PubMed Web of Science ®Google Scholar
• Falanga V Saap LJ Ozonoff A Wound bed score and its correlation with healing of chronic wounds Dermatol Ther 2006 19 6 383 390 17199681
   PubMed Web of Science ®Google Scholar
• Kurz X Kahn SR Abenhaim L Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic Studies Int Angiol 1999 18 2 83 102 10424364
   PubMed Web of Science ®Google Scholar
• Scondotto G Aloisi D Ferrari P Treatment of venous leg ulcers with Sulodexide Angiology 1999 50 1 883 889 10580352
   PubMed Web of Science ®Google Scholar
• Coccheri S Scondotto G Agnelli G Aloisi D Palazzini E Zamboni V SUAVIS group Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers Thromb Haemost 2002 87 6 947 952 12083500
   PubMed Web of Science ®Google Scholar
• Kucharzewski M Franek A Koziolek H Treatment of venous leg ulcers with Sulodexide Phlebologie 2003 32 115 120
   Web of Science ®Google Scholar
• Arosio E Ferrari G Santoro L Gianese F Coccheri S Mesoglycan Venous Insufficiency Group A placebo-controlled, double blind study of mesoglycan in the treatment of chronic venous ulcers Eur J Vasc Endovasc Surg 2001 22 4 365 372 11563899
   PubMed Web of Science ®Google Scholar
• Nelson EA Venous leg ulcers Clin Evid 2011 12 1902
   Google Scholar
• Kearon C Kahan SR Agnelli G Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed) Chest 2008 133 454S 545S 18574272
   PubMed Web of Science ®Google Scholar
• Baigent C Blackwell L Collins R Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 2009 373 1849 1860 19482214
   PubMed Web of Science ®Google Scholar
• Condorelli M Chiariello M Dagianti A IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction J Am Coll Cardiol 1994 23 1 27 34 8277091
   PubMed Web of Science ®Google Scholar
• Coccheri S Palareti G The cardiovascular risk burden of intermittent claudication Eur Heart J 2002 4 Suppl B B46 B49
   Web of Science ®Google Scholar
• Criqui MH Denenberg JO Langer RD Fronek A The epidemiology of peripheral arterial disease: importance of identifying the population at risk Vasc Med 1997 2 221 226 9546971
   PubMedGoogle Scholar
• Cicco G Stingi GD Vicenti P Tarallo MS Pirrelli A Hemorheology and tissue oxygenation in hypertensives with lipoidoproteinosis and peripheral occlusive arterial disease (POAD) treated with sulodexide and pravastatine and evaluated with laser assisted optical rotational red cell analyzer (LORCA) and transcutaneous oxymetry Min Cardioangiol 1999 47 351 359
   Google Scholar
• Gaddi A Galletti C Illuminati B Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease J Int Med Res 1996 24 389 406 8895043
   PubMed Web of Science ®Google Scholar
• Shustov SB Controlled clinical trial on the efficacy and safety of oral sulodexide in patients with peripheral occlusive arterial disease Curr Med Res Opin 1997 13 19 573 582 9327192
   PubMed Web of Science ®Google Scholar
• Lasierra-Cirujeda J Coronel P Aza MJ Gimeno M Use of sulodexide in patients with peripheral vascular disease J Blood Med 2010 1 105 115 22282689
   PubMedGoogle Scholar
• Stella A Tarantini G Palareti G Pharmacological therapy after carotid endoarterectomy: heparin, sulodexide, ticlopidine G Ital Chir Vasc 1999 6 161 179
   Google Scholar
• Parnetti L Mari D Abate G Vascular dementia Italian sulodexide study (VA.D.I.S.S.). Clinical and biological results Thromb Res 1997 87 2 225 233 9259113
   PubMed Web of Science ®Google Scholar
• Coccheri S Approaches to prevention of cardiovascular complications and events in diabetes mellitus Drugs 2007 67 7 997 1026 17488145
   PubMed Web of Science ®Google Scholar
• Weiss R Niecestro R Raz I The role of Sulodexide in the treatment of diabetic nephropathy Drugs 2007 67 18 2681 2696 18062718
   PubMed Web of Science ®Google Scholar
• Masola V Onisto M Zaza G Lupo A Gambaro G A new mechanism of action of Sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2 induced renal epithelial mesenchymal transition J Transl Med 2012 10 213 23095131
   PubMed Web of Science ®Google Scholar
• Ciszewicz M Polubinska A Antoniewicz A Suminska-Janinska K Breborowicz A Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytoxicity Transl Res 2009 153 3 118 123 19218094
   PubMed Web of Science ®Google Scholar
• Shu J Zeng LY Lin KY Renal protective effects of Sulodexide in diabetic rats and its antioxidative mechanism Nan Fang Yi Ke Da Xue Xue Bao 2009 29 4 778 780 Chinese 19403420
   PubMedGoogle Scholar
• Yung S Chau MK Zhang CZ Chan TM Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy PLoS One 2013 8 1 e54501 23349910
   PubMed Web of Science ®Google Scholar
• Cha JJ Kang YS Hyun YY Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats Life Sci 2013 92 23 118 124
   Web of Science ®Google Scholar
• Chen S Fang Z Zhu Z Deng A Liu J Zhang C Protective effect of sulodexide on podocyte injury in adriamycin nephropaty rats J Huazhong Univ Sci Technolog Med Sci 2009 29 6 715 719 20037813
   PubMedGoogle Scholar
• Rossini M Naito T Yang H Sulodexide ameliorates early but not late kidney disease in models of radiation nephropaty and diabetic nephropaty Nephrol Dial Transplant 2010 25 6 1803 1810 20061322
   PubMed Web of Science ®Google Scholar
• Gaddi AV Cicero AF Gambaro G Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered Int J Nephrol Renovasc Dis 2010 3 99 105 21694935
   PubMedGoogle Scholar
• Li P Ma LL Xie RJ Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure Acta Pharmacol Sin 2012 33 5 644 651 22555371
   PubMed Web of Science ®Google Scholar
• Gambaro G Kinalska I Oksa A Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.s: randomized trial J Am Soc Nephrol 2002 13 6 1615 1625 12039991
   PubMed Web of Science ®Google Scholar
• Blouza S Dakhii S Abid H Aissaoui M DAVET (Diabetic Albuminuria Vessel Tunisia) Study Investigators Efficacy of low-dose oral Sulodexide in the management of diabetic nephropathy J Nephrol 2010 23 4 415 424 20175052
   PubMed Web of Science ®Google Scholar
• Bang K Chin HJ Chae DW Anti-proteinuric effect of sulodexide in immunoglobulin a nephropathy Yonsei Med J 2011 52 4 588 594 21623600
   PubMed Web of Science ®Google Scholar
• Heersprink HL Greene T Lewis JB Collaborative Study Group Effect of Sulodexide in patients with type 2 diabetes and persistent albuminuria Nephrol Dial Transplant 2008 23 1946 1954 18089623
   PubMed Web of Science ®Google Scholar
• Lewis EJ Lewis JB Greene T Collaborative Study Group Sulodexide for kidney protection in type 2 diabetes patients with macroalbuminuria: a randomized controlled trial Am J Kidney Dis 2011 58 5 729 736 21872376
   PubMed Web of Science ®Google Scholar
• Packham DK Wolfe R Reutens AT Collaborative Study Group Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy J Am Soc Nephrol 2012 23 123 130 22034636
   PubMed Web of Science ®Google Scholar
• House AA Weir MA Sulodexide for diabetic nephropathy: another one bites the dust Am J Kidney Dis 2011 58 5 692 694 22014634
   PubMed Web of Science ®Google Scholar
• Coccheri S Game not over for sulodexide Am J Kidney Dis 2012 59 3 467 22340910
   PubMed Web of Science ®Google Scholar
• Gaddi AV Benedetto D Surrogate versus clinical end points and venture capital companies: the doubts of a clinician Am J Kidney Dis 2012 60 1 168 171 22709597
   PubMed Web of Science ®Google Scholar
• Gambaro G Discounting the efficacy of sulodexide in diabetic nephropathy is premature Am J Kidney Dis 2012 69 1 169 170 22709598
   PubMed Web of Science ®Google Scholar
• Rubbi F Caramazza R Boccia S The effects of sulodexide on diabetic retinopathy Minerva Cardioangiol 2000 48 Suppl 1 81 82
   Google Scholar
• Karimov KT Shakhmaliyeva AM Effect of sulodexide on non-proliferative diabetic retinopathy Azerbaijan Med J 2002 1 72 76
   Google Scholar
• Chin HS Kang SW Kawak HW Effect of sulodexide in diabetic patients with mild to moderate nonproliferative retinopathy AAO 2011 – Annual Meeting of the American Academy of Ophtalmology Abstract 498 p221
   Google Scholar
• Jin HY Lee KE Song SK Sulodexide prevents peripheral nerve damage in streptozotocin induced diabetic rats Eur J Pharmacol 2012 674 2–3 217 226 21641343
   PubMed Web of Science ®Google Scholar
• Koblik T Sieradzki J Sendur R The effect of insulin and sulodexide (Vessel Due F) on diabetic foot syndrome. Pilot study in elderly patients J Diabetes Complications 2001 15 2 69 74 11274902
   PubMed Web of Science ®Google Scholar
• Anfossi DG Bella GM Chiriotti S Comparative study of two different protocols in the treatment of retinal vein occlusion Minerva Opthalmol 1992 34 29 36
   Google Scholar
• Szafilk J Kaminska A Usefulness of Vessel Due F (sulodexide) in treatment of patients with diabetic retinopathy, senile macular degeneration and retinal vein occlusion Okulistyka 2000 3 1 4
   Google Scholar
• Guidetti G Treatment of vascular vertigo in outpatients: multicentre experience (VascVert study) Otorinolaringol 2005 55 237 246
   Google Scholar
• Neri G Baffa C De Stefano A Management of tinnitus: oral treatment with melatonin and sulodexide J Biol Regul Homeost Agents 2009 23 2 103 110 19589291
   PubMed Web of Science ®Google Scholar